{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:32:34Z","timestamp":1781782354898,"version":"3.54.5"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","amjmedsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.amjms.2016.10.009","type":"journal-article","created":{"date-parts":[[2016,10,29]],"date-time":"2016-10-29T15:16:54Z","timestamp":1477754214000},"page":"76-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Erythropoietin and Nonhematopoietic Effects"],"prefix":"10.1016","volume":"353","author":[{"given":"Alireza","family":"Nekoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.amjms.2016.10.009_bib1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.amjms.2016.10.009_bib2","first-page":"S2","article-title":"Pathophysiology of renal anemia","volume":"53","author":"Eckardt","year":"2000","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0306-9877(02)00337-7","article-title":"Is recombinant human erythropoietin (rh-epo) more than just a treatment of anemia in cancer and chemotherapy?","volume":"60","author":"Taylor","year":"2003","journal-title":"Med Hypotheses"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10741-008-9086-x","article-title":"Iron and anemia in human biology: a review of mechanisms","volume":"13","author":"Handelman","year":"2008","journal-title":"Heart Fail Rev"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.clinthera.2006.06.003","article-title":"Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature","volume":"28","author":"Ross","year":"2006","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/10245332.2015.1101972","article-title":"Erythropoietin in anemia of unknown etiology: a systematic review and meta-analysis","volume":"21","author":"Sriram","year":"2016","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.amjms.2016.10.009_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7326\/M15-1839","article-title":"The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis","volume":"164","author":"Collister","year":"2016","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.amjms.2016.10.009_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/eci.12357","article-title":"High-dose erythropoietin for tissue protection","volume":"44","author":"Lund","year":"2014","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12028-012-9710-4","article-title":"A pilot study of darbepoetin alfa for prophylactic neuroprotection in aortic surgery","volume":"18","author":"Messe","year":"2013","journal-title":"Neurocrit Care"},{"issue":"8","key":"10.1016\/j.amjms.2016.10.009_bib10","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1073\/pnas.0630444100","article-title":"Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling","volume":"100","author":"Calvillo","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1046\/j.1460-9568.2003.02875.x","article-title":"Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury","volume":"18","author":"Campana","year":"2003","journal-title":"Eur J Neurosci"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib12","doi-asserted-by":"crossref","first-page":"e28849","DOI":"10.5812\/aapm.28849","article-title":"Neuroprotective effect of erythropoietin in postoperation cervical spinal cord injury: case report and review","volume":"5","author":"Nekoui","year":"2015","journal-title":"Anesth Pain Med"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1073858403259187","article-title":"Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go?","volume":"10","author":"Grasso","year":"2004","journal-title":"Neuroscientist"},{"key":"10.1016\/j.amjms.2016.10.009_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2119\/molmed.2011.00414","article-title":"The receptor that tames the innate immune response","volume":"18","author":"Brines","year":"2012","journal-title":"Mol Med"},{"issue":"5","key":"10.1016\/j.amjms.2016.10.009_bib15","first-page":"256","article-title":"Anaemia: regulation of renal erythropoietin via HIF","volume":"12","author":"Edwards","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.ki.5001546","article-title":"Discovering erythropoietin\u05f3s extra-hematopoietic functions: biology and clinical promise","volume":"70","author":"Brines","year":"2006","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.amjms.2016.10.009_bib17","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1182\/blood.V93.11.3757","article-title":"Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells)","volume":"93","author":"Bao","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.10.009_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1152\/physiol.00045.2008","article-title":"Regulation of oxygen homeostasis by hypoxia-inducible factor 1","volume":"24","author":"Semenza","year":"2009","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.amjms.2016.10.009_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","article-title":"Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology","volume":"9","author":"Semenza","year":"2014","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/apha.12613","article-title":"Adaptive response to hypoxia and remote ischaemia pre-conditioning: a new hypoxia-inducible factors era in clinical medicine","volume":"216","author":"Heyman","year":"2016","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.amjms.2016.10.009_bib21","first-page":"953264","article-title":"Erythropoietin in brain development and beyond","volume":"2012","author":"Alnaeeli","year":"2012","journal-title":"Anat Res Int"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.brainresrev.2009.09.006","article-title":"The role and regulation of hypoxia-inducible factor-1alpha expression in brain development and neonatal hypoxic-ischemic brain injury","volume":"62","author":"Fan","year":"2009","journal-title":"Brain Res Rev"},{"issue":"10","key":"10.1016\/j.amjms.2016.10.009_bib23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.braindev.2014.01.005","article-title":"Erythropoietin improves brain development in short-term hypoxia in rat embryo cultures","volume":"36","author":"Torun","year":"2014","journal-title":"Brain Dev"},{"issue":"5","key":"10.1016\/j.amjms.2016.10.009_bib24","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2005-06-2304","article-title":"AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation","volume":"107","author":"Ghaffari","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.transproceed.2016.01.009","article-title":"Erythropoietin receptor activation protects the kidney from ischemia\/reperfusion-induced apoptosis by activating ERK\/p53 signal pathway","volume":"48","author":"Zou","year":"2016","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.amjms.2016.10.009_bib26","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1271\/bbb.64.1775","article-title":"Erythropoietin: multiple physiological functions and regulation of biosynthesis","volume":"64","author":"Sasaki","year":"2000","journal-title":"Biosci Biotechnol Biochem"},{"issue":"8","key":"10.1016\/j.amjms.2016.10.009_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2169\/internalmedicine.43.649","article-title":"Molecular biology of erythropoietin","volume":"43","author":"Jelkmann","year":"2004","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.mcn.2005.04.009","article-title":"Erythropoietin promotes regeneration of adult CNS neurons via Jak2\/Stat3 and PI3K\/AKT pathway activation","volume":"29","author":"Kretz","year":"2005","journal-title":"Mol Cell Neurosci"},{"issue":"3","key":"10.1016\/j.amjms.2016.10.009_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11239-008-0212-3","article-title":"Erythropoietin in heart and vessels: focus on transcription and signalling pathways","volume":"26","author":"Marzo","year":"2008","journal-title":"J Thromb Thrombolysis"},{"issue":"13","key":"10.1016\/j.amjms.2016.10.009_bib30","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1096\/fj.02-0168fje","article-title":"Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB","volume":"16","author":"La Ferla","year":"2002","journal-title":"FASEB J"},{"issue":"12","key":"10.1016\/j.amjms.2016.10.009_bib31","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1096\/fj.02-1134fje","article-title":"A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA","volume":"17","author":"Imagawa","year":"2003","journal-title":"FASEB J"},{"issue":"12","key":"10.1016\/j.amjms.2016.10.009_bib32","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.exphem.2008.08.003","article-title":"Erythropoietins: a common mechanism of action","volume":"36","author":"Elliott","year":"2008","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jama.293.1.90","article-title":"New avenues of exploration for erythropoietin","volume":"293","author":"Maiese","year":"2005","journal-title":"J Am Med Assoc"},{"issue":"11\u201312","key":"10.1016\/j.amjms.2016.10.009_bib34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/BF01936936","article-title":"Role of erythropoietin in adaptation to hypoxia","volume":"46","author":"Scholz","year":"1990","journal-title":"Experientia"},{"issue":"3","key":"10.1016\/j.amjms.2016.10.009_bib35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1046\/j.1523-1755.1999.055003808.x","article-title":"Human, rat, and mouse kidney cells express functional erythropoietin receptors","volume":"55","author":"Westenfelder","year":"1999","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib36","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1006\/bbrc.2001.5085","article-title":"Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells","volume":"284","author":"Ammarguellat","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1006\/mvre.2002.2426","article-title":"Erythropoietin and VEGF exhibit equal angiogenic potential","volume":"64","author":"Jaquet","year":"2002","journal-title":"Microvasc Res"},{"issue":"9","key":"10.1016\/j.amjms.2016.10.009_bib38","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1097\/00004872-199917090-00003","article-title":"The effect of erythropoietin on interleukin-1beta mediated increase in nitric oxide synthesis in vascular smooth muscle cells","volume":"17","author":"Akimoto","year":"1999","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib39","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1681\/ASN.2004090735","article-title":"Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase","volume":"16","author":"Scalera","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.amjms.2016.10.009_bib40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/ndt\/14.3.597","article-title":"Human recombinant erythropoietin inhibits interleukin-1beta-stimulated nitric oxide and cyclic guanosine monophosphate production in cultured rat vascular smooth-muscle cells","volume":"14","author":"Kusano","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00004872-200102000-00005","article-title":"Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells","volume":"19","author":"Akimoto","year":"2001","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/pr.2013.155","article-title":"Erythropoietin signaling promotes oligodendrocyte development following prenatal systemic hypoxic-ischemic brain injury","volume":"74","author":"Jantzie","year":"2013","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1242\/dev.129.2.505","article-title":"Erythropoietin receptor signalling is required for normal brain development","volume":"129","author":"Yu","year":"2002","journal-title":"Development"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.pediatrneurol.2014.06.008","article-title":"Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection","volume":"51","author":"Rangarajan","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib45","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1542\/peds.2008-3553","article-title":"Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy","volume":"124","author":"Zhu","year":"2009","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib46","doi-asserted-by":"crossref","first-page":"e11016","DOI":"10.1371\/journal.pone.0011016","article-title":"Erythropoietin amplifies stroke-induced oligodendrogenesis in the rat","volume":"5","author":"Zhang","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib47","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1089\/neu.2011.1827","article-title":"Neuroprotection with an erythropoietin mimetic peptide (pHBSP) in a model of mild traumatic brain injury complicated by hemorrhagic shock","volume":"29","author":"Robertson","year":"2012","journal-title":"J Neurotrauma"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib48","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1542\/peds.2013-4307","article-title":"Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo","volume":"133","author":"Ohls","year":"2014","journal-title":"Pediatrics"},{"issue":"suppl 3","key":"10.1016\/j.amjms.2016.10.009_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dmcn.12730","article-title":"Erythropoietin: a novel therapy for hypoxic-ischaemic encephalopathy?","volume":"57","author":"Wu","year":"2015","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib50","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-011-9579-6","article-title":"Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy","volume":"41","author":"Hernandez","year":"2012","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00125-010-1727-7","article-title":"Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina","volume":"53","author":"Wang","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjms.2016.10.009_bib52","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exer.2012.11.001","article-title":"Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats","volume":"106","author":"Mitsuhashi","year":"2013","journal-title":"Exp Eye Res"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib53","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1167\/iovs.07-0721","article-title":"Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes","volume":"49","author":"Zhang","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib54","doi-asserted-by":"crossref","first-page":"e7291","DOI":"10.5812\/aapm.7291","article-title":"Human erythropoietin effect in postoperative visual loss following spine surgery: a case report","volume":"4","author":"Hassani","year":"2014","journal-title":"Anesth Pain Med"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib55","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3171\/spi.2006.4.4.310","article-title":"Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative","volume":"4","author":"Grasso","year":"2006","journal-title":"J Neurosurg Spine"},{"issue":"5681","key":"10.1016\/j.amjms.2016.10.009_bib56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1098313","article-title":"Derivatives of erythropoietin that are tissue protective but not erythropoietic","volume":"305","author":"Leist","year":"2004","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.amjms.2016.10.009_bib57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.clineuro.2007.05.013","article-title":"The role of erythropoietin in central and peripheral nerve injury","volume":"109","author":"Lykissas","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","article-title":"Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system","volume":"6","author":"Sir\u00e9n","year":"2009","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.amjms.2016.10.009_bib59","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3174\/ajnr.A1820","article-title":"Erythropoietin promotes functional recovery and enhances nerve regeneration after peripheral nerve injury in rats","volume":"31","author":"Yin","year":"2010","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib60","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20021067","article-title":"Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis","volume":"198","author":"Villa","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.amjms.2016.10.009_bib61","doi-asserted-by":"crossref","first-page":"453179","DOI":"10.1155\/2011\/453179","article-title":"Erythropoietin: recent developments in the treatment of spinal cord injury","volume":"2011","author":"Carelli","year":"2011","journal-title":"Neurol Res Int"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1602\/neurorx.1.1.80","article-title":"Neuroprotection and acute spinal cord injury: a reappraisal","volume":"1","author":"Hall","year":"2004","journal-title":"NeuroRx"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/pr.2012.148","article-title":"Hypothermia plus erythropoietin for neonatal neuroprotection? Commentary on Fan et al and Fang et al","volume":"73","author":"Juul","year":"2013","journal-title":"Pediatr Res"},{"issue":"5","key":"10.1016\/j.amjms.2016.10.009_bib64","doi-asserted-by":"crossref","first-page":"e0127629","DOI":"10.1371\/journal.pone.0127629","article-title":"The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study","volume":"10","author":"Vinberg","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clon.2006.10.009","article-title":"Functional and pharmacokinetic outcomes after a single intravenous infusion of recombinant human erythropoietin in patients with malignant extradural spinal cord compression","volume":"19","author":"Loblaw","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.amjms.2016.10.009_bib66","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1073\/pnas.0307823100","article-title":"Erythropoietin both protects from and reverses experimental diabetic neuropathy","volume":"101","author":"Bianchi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.amjms.2016.10.009_bib67","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMcibr041121","article-title":"Erythropoietin for neurologic protection and diabetic neuropathy","volume":"350","author":"Lipton","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.amjms.2016.10.009_bib68","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12630-009-9111-0","article-title":"Effects of recombinant human erythropoietin on neuropathic pain and cerebral expressions of cytokines and nuclear factor-kappa B","volume":"56","author":"Jia","year":"2009","journal-title":"Can J Anaesth"},{"issue":"5","key":"10.1016\/j.amjms.2016.10.009_bib69","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2176\/nmc.50.361","article-title":"Effect of recombinant human erythropoietin on serum S100B protein and interleukin-6 levels after traumatic brain injury in the rat","volume":"50","author":"Bian","year":"2010","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"5\u20136","key":"10.1016\/j.amjms.2016.10.009_bib70","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/17482960902995246","article-title":"Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability","volume":"10","author":"Lauria","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"issue":"Pt 10","key":"10.1016\/j.amjms.2016.10.009_bib71","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/brain\/awm203","article-title":"Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis","volume":"130","author":"Ehrenreich","year":"2007","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/j.amjms.2016.10.009_bib72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jns.2013.11.015","article-title":"Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson\u05f3s disease","volume":"337","author":"Jang","year":"2014","journal-title":"J Neurol Sci"},{"issue":"14","key":"10.1016\/j.amjms.2016.10.009_bib73","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2174\/092986708784567671","article-title":"Old friends in new constellations\u2014the hematopoetic growth factors G-CSF, GM-CSF, and EPO for the treatment of neurological diseases","volume":"15","author":"Maurer","year":"2008","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12031-013-0208-0","article-title":"EPO-dependent activation of PI3K\/Akt\/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson\u05f3s disease","volume":"53","author":"Jia","year":"2014","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.amjms.2016.10.009_bib75","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2119\/molmed.2013.00122","article-title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density","volume":"19","author":"Dahan","year":"2013","journal-title":"Mol Med"},{"issue":"38","key":"10.1016\/j.amjms.2016.10.009_bib76","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.2174\/1381612811319380011","article-title":"Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy","volume":"19","author":"Merelli","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib77","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/187152712800792820","article-title":"New agents promote neuroprotection in Parkinson\u05f3s disease models","volume":"11","author":"Santos","year":"2012","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.amjms.2016.10.009_bib78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40478-014-0084-z","article-title":"Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"2","author":"Girolamo","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.amjms.2016.10.009_bib79","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1742-2094-10-156","article-title":"Erythropoietin improves motor and cognitive deficit, axonal pathology, and neuroinflammation in a combined model of diffuse traumatic brain injury and hypoxia, in association with upregulation of the erythropoietin receptor","volume":"10","author":"Hellewell","year":"2013","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00008506-200604000-00007","article-title":"The brain erythropoietin system and its potential for therapeutic exploitation in brain disease","volume":"18","author":"Hasselblatt","year":"2006","journal-title":"J Neurosurg Anesthesiol"},{"issue":"3","key":"10.1016\/j.amjms.2016.10.009_bib81","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00213-011-2511-1","article-title":"Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression","volume":"219","author":"Miskowiak","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib82","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/npp.2013.335","article-title":"Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"39","author":"Miskowiak","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.amjms.2016.10.009_bib83","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1440-1819.2012.02359.x","article-title":"Treating patients with schizophrenia deficit with erythropoietin?","volume":"66","author":"Fond","year":"2012","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mp.2010.51","article-title":"Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia","volume":"16","author":"Wustenberg","year":"2011","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib85","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/j.jrn.2007.10.029","article-title":"Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition","volume":"18","author":"Ehrenreich","year":"2008","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.amjms.2016.10.009_bib86","doi-asserted-by":"crossref","first-page":"373781","DOI":"10.1155\/2011\/373781","article-title":"The effects of erythropoietin dose titration during high-fat diet-induced obesity","volume":"2011","author":"Foskett","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"10.1016\/j.amjms.2016.10.009_bib87","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1677\/JOE-09-0425","article-title":"Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models","volume":"205","author":"Katz","year":"2010","journal-title":"J Endocrinol"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib88","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.plipres.2004.03.001","article-title":"Leptin: linking adipocyte metabolism with cardiovascular and autoimmune diseases","volume":"43","author":"Peelman","year":"2004","journal-title":"Prog Lipid Res"},{"issue":"13","key":"10.1016\/j.amjms.2016.10.009_bib89","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1084\/jem.20100665","article-title":"Erythropoietin protects against diabetes through direct effects on pancreatic beta cells","volume":"207","author":"Choi","year":"2010","journal-title":"J Exp Med"},{"issue":"41","key":"10.1016\/j.amjms.2016.10.009_bib90","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0406491101","article-title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","volume":"101","author":"Brines","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.amjms.2016.10.009_bib91","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.jacc.2006.08.031","article-title":"Protective effects of erythropoietin in cardiac ischemia: from bench to bedside","volume":"48","author":"Lipsic","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib92","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2003-01-0223","article-title":"Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization","volume":"102","author":"Heeschen","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.amjms.2016.10.009_bib93","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/152581602321080529","article-title":"Angiogenesis and plasticity: role of erythropoietin in vascular systems","volume":"11","author":"Chong","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"issue":"2","key":"10.1016\/j.amjms.2016.10.009_bib94","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1432-1033.1996.0494u.x","article-title":"Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA","volume":"239","author":"Yamaji","year":"1996","journal-title":"Eur J Biochem"},{"issue":"9","key":"10.1016\/j.amjms.2016.10.009_bib95","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1046\/j.1460-9568.2003.02987.x","article-title":"Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability","volume":"18","author":"Martinez-Estrada","year":"2003","journal-title":"Eur J Neurosci"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib96","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.RES.0000137877.89448.78","article-title":"Endothelial progenitor cells: characterization and role in vascular biology","volume":"95","author":"Urbich","year":"2004","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.amjms.2016.10.009_bib97","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/01.CCM.0000206468.18653.EC","article-title":"Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds","volume":"34","author":"Galeano","year":"2006","journal-title":"Crit Care Med"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291630595X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291630595X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T20:15:19Z","timestamp":1657570519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000296291630595X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S000296291630595X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2016.10.009","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythropoietin and Nonhematopoietic Effects","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2016.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Southern Society for Clinical Investigation. Published by All rights reserved.","name":"copyright","label":"Copyright"}]}}